SCHEMBL9768531

SCHEMBL9768531

CNCc1ccccc1S(=O)(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MYC P01106 1/20 0.44
MMP1 P03956 5/20 0.39
MMP2 P08253 5/20 0.39
MMP3 P08254 5/20 0.39
MMP9 P14780 5/20 0.39
MMP8 P22894 5/20 0.39
MMP12 P39900 5/20 0.39
MMP13 P45452 5/20 0.39
MMP14 P50281 5/20 0.39
MMP16 P51512 5/20 0.39
ADAM17 P78536 1/20 0.39
SLC6A4 P31645 3/20 0.39
SLC6A2 P23975 3/20 0.39
SLC6A3 Q01959 3/20 0.39
LTA4H P09960 1/20 0.39
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
ALDH1A1 P00352 1/20 0.38
PKM P14618 1/20 0.38
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8339184 0.82 ADRA1D (0.43) MMP1MMP2MMP3MMP9MMP8
SCHEMBL8077339 0.82 TTR (0.42) MYCMMP1MMP2MMP3MMP9
SCHEMBL6275541 0.82 TTR (0.50) CA2CYP3A4IFNAR1LMNATDP1
Water SCHEMBL29718461 0.82 CTSB (0.50) MYCLMNATTR
SCHEMBL8719378 0.81 HIF1A (0.46) MYCSLC6A4SLC6A2SLC6A3CA1
SCHEMBL14991455 0.81 MYC (0.47) MYCMMP1MMP2MMP3MMP9
SCHEMBL31425768 0.81 MYC (0.47) MYCMMP1MMP2MMP3MMP9
SCHEMBL31425767 0.81 MYC (0.47) MYCMMP1MMP2MMP3MMP9
SCHEMBL9769575 0.81 MAPT (0.42) MYCMMP1MMP2MMP3MMP9
SCHEMBL3363314 0.81 CA2 (0.49) SLC6A4SLC6A2SLC6A3CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190753-A1 Methods and Compositions for Treating Amyloid-Related Diseases BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) 2010-07-29 US disclosed
US-7598269-B2 Methods and compositions for treating amyloid-related diseases BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) 2009-10-06 US disclosed
US-20080015180-A1 Methods and compositions for treating amyloid-related diseases NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2008-01-17 US disclosed
US-7244764-B2 Methods and compositions for treating amyloid-related diseases NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2007-07-17 US disclosed
US-7244764-B2 Methods and compositions for treating amyloid-related diseases NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2007-07-17 US disclosed
US-5053494-A FIBER REACTIVE POLYAZO DYE HAVING TWO VINYLSULFONE TYPE REACTIVE GROUPS THROUGH TRIAZINYL BRIDGING GROUP SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1991-10-01 US disclosed
EP-0266774-B1 POLYAZO COMPOUND HAVING TWO VINYLSULFONE TYPE FIBER REACTIVE GROUPS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1991-08-28 EP disclosed
EP-0266774-A1 Polyazo compound having two vinylsulfone type fiber reactive groups SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1988-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190753-A1 Methods and Compositions for Treating Amyloid-Related Diseases APP, PSEN1, PSEN2 MYC 3501/4885MMP1 903/4885MMP2 1137/4885
US-20080015180-A1 Methods and compositions for treating amyloid-related diseases APP, PSEN1, PSEN2 MYC 3501/4885MMP1 903/4885MMP2 1137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.